ACHILLION PHARMACEUTICALS IN's ticker is ACHN and the CUSIP is 00448Q201. A total of 106 filers reported holding ACHILLION PHARMACEUTICALS IN in Q3 2013. The put-call ratio across all filers is 0.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $5,000 | -66.7% | 817 | -80.5% | 0.00% | -100.0% |
| Q3 2019 | $15,000 | -37.5% | 4,189 | -52.6% | 0.00% | -50.0% |
| Q2 2019 | $24,000 | +50.0% | 8,837 | +99.2% | 0.00% | +100.0% |
| Q3 2018 | $16,000 | – | 4,437 | – | 0.00% | – |
| Q4 2017 | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
| Q3 2017 | $48,000 | +433.3% | 10,659 | +365.3% | 0.00% | +300.0% |
| Q4 2016 | $9,000 | +800.0% | 2,291 | +2191.0% | 0.00% | – |
| Q3 2016 | $1,000 | -88.9% | 100 | -91.0% | 0.00% | -100.0% |
| Q1 2016 | $9,000 | -89.4% | 1,107 | -88.5% | 0.00% | -87.5% |
| Q2 2015 | $85,000 | -48.5% | 9,610 | -42.4% | 0.01% | -60.0% |
| Q1 2015 | $165,000 | +1275.0% | 16,696 | +1650.1% | 0.02% | +1900.0% |
| Q4 2014 | $12,000 | -77.4% | 954 | -82.1% | 0.00% | -83.3% |
| Q3 2014 | $53,000 | -10.2% | 5,322 | -70.2% | 0.01% | -40.0% |
| Q4 2013 | $59,000 | +63.9% | 17,839 | +309.1% | 0.01% | +233.3% |
| Q2 2013 | $36,000 | – | 4,361 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 13,633,220 | $56,305,000 | 7.98% |
| BVF INC/IL | 2,423,300 | $10,008,000 | 2.01% |
| EMORY UNIVERSITY | 454,102 | $1,875,000 | 1.85% |
| DAFNA Capital Management LLC | 196,500 | $812,000 | 0.71% |
| Orbimed Advisors | 13,107,200 | $54,133,000 | 0.69% |
| RTW INVESTMENTS, LP | 286,285 | $1,182,000 | 0.44% |
| Marcus Capital, LLC | 100,000 | $413,000 | 0.44% |
| Rock Springs Capital Management LP | 1,375,000 | $5,679,000 | 0.38% |
| Spark Investment Management LLC | 978,600 | $4,041,000 | 0.33% |
| Bellevue Group AG | 240,000 | $991,000 | 0.20% |